Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 8/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17454490 | 0.85 | KEAP1 (0.40) | PLATKEAP1NFE2L2SPRKDM4E | |
| SCHEMBL17437928 | 0.81 | SPR (0.49) | PLATKEAP1NFE2L2SPRKDM4E | |
| SCHEMBL21946618 | 0.80 | PLAT (0.39) | PLATDPP4 | |
| SCHEMBL21948590 | 0.79 | ROCK2 (0.39) | PLATROCK2 | |
| SCHEMBL23889193 | 0.78 | ROCK2 (0.38) | PLATROCK2 | |
| SCHEMBL19902682 | 0.78 | ROCK2 (0.52) | ROCK2 | |
| SCHEMBL21948585 | 0.76 | ROCK2 (0.39) | PLATROCK2 | |
| SCHEMBL21947307 | 0.76 | ROCK2 (0.37) | PLATROCK2 | |
| SCHEMBL21947213 | 0.76 | PLAT (0.39) | PLATROCK2 | |
| SCHEMBL21946550 | 0.75 | MAPK8 (0.38) | PLATROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | PLAT 2610/4885KEAP1 247/4885NFE2L2 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.